Rat Model Of Hepatocellular Carcinoma Research Articles

Integrated Approach to Match Cancer Drug with Molecular Imaging Probe to Quantify Targeting and Predict Response.

HomeRadiology: Imaging CancerVol. 2, No. 6 PreviousNext Research HighlightsFree AccessIntegrated Approach to Match Cancer Drug with Molecular Imaging Probe to Quantify Targeting and Predict ResponseGary D. LukerGary D. LukerGary D. LukerPublished Online:Nov 27 2020https://doi.org/10.1148/rycan.2020209035MoreSectionsPDF ToolsImage ViewerAdd to favoritesCiteTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinked InEmail Take-Away Points■ Major Focus: Identifying targeted cancer drugs and matching imaging agents through data from functional genetic screens.■ Key Result: Functional genetic screens showed that hepatocellular carcinoma is vulnerable to inhibition of lactate dehydrogenase, an enzyme that can be imaged by MR spectroscopy of hyperpolarized [1-13C]-pyruvate.■ Impact: The study opens a paradigm to integrate selection of a drug target and corresponding molecular imaging probe to quantify drug targeting and predict response to therapy.Drug development in oncology now focuses on targeting specific mutations and signaling pathways in cancer and stromal cells. Such drugs still fail in large numbers of patients due in part to a lack of imaging methods to accurately detect successful inhibition of a drug target. To overcome this limitation, Perkons et al analyzed publicly available data from screens of cancer cells for targetable vulnerabilities defined by CRISPR gene editing technology, a transformative technique recognized with the 2020 Nobel Prize in Chemistry. The investigators matched potential drug targets with enzymes and pathways that could be imaged with available imaging probes for hyperpolarized MR spectroscopy. Through this process, the team identified lactate dehydrogenase, an enzyme in glycolytic metabolism, as a therapeutic vulnerability in hepatocellular carcinoma and determined that hyperpolarized [1-13C]-pyruvate could be used to image inhibition of this enzyme.Using a rat model of hepatocellular carcinoma in a background of cirrhosis, dose-dependent inhibition of lactate dehydrogenase with a small molecule compound could be quantified by MR spectroscopy with hyperpolarized [1-13C]-pyruvate. The extent of inhibition correlated with effects of treatment to inhibit doubling of tumor volume measured by MRI. Increased levels of alanine, a metabolic byproduct of pyruvate, predicted successful response to therapy. These results establish an integrated approach to match a drug with a specific molecular imaging probe, which promises to improve the ability to rapidly predict response to cancer therapy with targeted inhibitors.Highlighted ArticlePerkons NR, Johnson O, Pilla G, et al. Functional genetic screening enables theranostic molecular imaging in cancer. Clin Cancer Res 2020; 26(17):4581–4589. doi: 10.1158/1078-0432.CCR-20-0826Highlighted ArticlePerkons NR, Johnson O, Pilla G et al. Functional genetic screening enables theranostic molecular imaging in cancer. Clin Cancer Res 2020; 26(17):4581–4589. doi: 10.1158/1078-0432.CCR-20-0826 Crossref, Medline, Google ScholarArticle HistoryPublished online: Nov 27 2020 FiguresReferencesRelatedDetailsRecommended Articles Monitoring Liver Tumor Ablation with MR Spectroscopy of Extracellular pHRadiology: Imaging Cancer2020Volume: 2Issue: 2Hyperpolarized 13C MRI: State of the Art and Future DirectionsRadiology2019Volume: 291Issue: 2pp. 273-284Precision Medicine and Radiogenomics in Breast Cancer: New Approaches toward Diagnosis and TreatmentRadiology2018Volume: 287Issue: 3pp. 732-747Immunotherapy and the Interventional Oncologist: Challenges and Opportunities—A Society of Interventional Oncology White PaperRadiology2019Volume: 292Issue: 1pp. 25-34Proliferative versus Nonproliferative Hepatocellular Carcinoma: Clinical and Imaging ImplicationsRadiology2021Volume: 300Issue: 3pp. 583-585See More RSNA Education Exhibits Assessing Immunotherapy with Functional and Molecular Imaging and Radiomics: Whence and WitherDigital Posters2019Precision Imaging Biomarkers for Enhanced Detection and Characterization of Primary and Metastatic Hepatic TumorsDigital Posters2017Imaging Biomarkers in Targeted Therapies: From Quantitative Imaging to RadiomicsDigital Posters2019 RSNA Case Collection Gallbladder CarcinomaRSNA Case Collection2021LI-RADS 4 RSNA Case Collection2021Primary HemochromatosisRSNA Case Collection2021 Vol. 2, No. 6 Metrics Downloaded 26 times Altmetric Score

Cationic Solid Lipid Nanoparticles of Resveratrol for Hepatocellular Carcinoma Treatment: Systematic Optimization, in vitro Characterization and Preclinical Investigation.

AimThe present study focuses on the development and evaluation of the resveratrol (RV)-loaded cationic solid lipid nanoparticles (RV-c-SLNs) for the management of hepatocellular carcinoma (HCC).Materials and MethodsOptimization of formulation was performed using factorial design, and further in vitro drug release, cytotoxicity, biodistribution, in vivo preclinical, and biochemical evaluation were carried out.ResultsThe optimized formulation exhibited uniform size, homogeneous disparity, positive zeta potential, and stability over 12-week storage at 25°C/60% RH. The in vitro drug release and cytotoxicity study showed 60% drug release within the first 6 hours and comparatively higher cytotoxicity on HepG2 cell line by resveratrol-solid lipid nanoparticle (RV-SLN) as compared to the RV solution. In addition, an anticancer action and biodistribution study on a rat model of HCC showed significant reduction of tumor volume and higher accumulation in the tumor tissue from RV-c-SLN (P<0.01) over RV solution and RV-SLN. Furthermore, RV-c-SLN showed significant down-regulation in the levels of pro-inflammatory cytokines and balancing of antioxidant enzymes. Histopathological investigation showed reduced occurrence of hepatic nodules, necrosis formation, infiltration of inflammatory cells, blood vessels inflammation, and cell swelling.ConclusionOverall, the obtained results construed that RV-c-SLN with improved antitumor activity as clearly evident from in vitro, in vivo, and biochemical investigations.

The Mutational and Transcriptional Landscapes of Hepatocarcinogenesis in a Rat Model.

SummaryHepatocellular carcinoma (HCC) initiation is characterized by stepwise accumulation of molecular alterations, during which the early events are largely unknown. Here, we presented a comprehensive genomic and transcriptomic landscape at stages of hepatitis, cirrhosis, and HCC by using a diethylnitrosamine-induced rat HCC model. We observed the early occurrence of gene instability and aberrant cancer associated signaling pathways in liver hepatitis. We further characterized the progressive molecular changes during hepatocarcinogenesis, wherein the intense rivalry between tumor-suppressive and oncogenic strengths occurred in cirrhosis stage. Despite the significant pathological difference, mutation signatures and expression landscape are highly similar between hepatitis and cirrhosis stages. Furthermore, we identified PI3K-Akt signaling pathway as a key pathway in the process of hepatocarcinogenesis through integrative analysis, and PIK3CD is a potential biomarker indicating HCC recurrence. The dynamic immune response during hepatocarcinogenesis, such as continuous decline of monocytes, suggests an immunological intervention strategy beyond chemoprevention for liver cancer.

Synergistic Effects of Ellagic Acid and Sorafenib on Hepatocytes and Mitochondria Isolated from a Hepatocellular Carcinoma Rat Model

Introduction Hepatocellular carcinoma (HCC) is one of the deadliest and most common cancers in humans worldwide. Today, common treatment options for HCC are not effective. The synergistic relationship between compounds of natural origin and the drugs used in the treatment of cancer has been described. Ellagic acid (EA) as a compound of natural origin induces cell death in various cancer cell lines. Aim: The aim of this study was to investigate the effects of the alone or combination of EA and sorafenib (SOR) on HCC hepatocytes viability and apoptosis signaling both in vitro and in vivo. Methods: The synergistic effects of EA and SOR were tested in an HCC rat model. This was followed by cellular and mitochondrial parameters. Results: Results showed that SOR and EA applied alone or in combination increased the reactive oxygen species (ROS), mitochondrial membrane potential (MMP), and cytochrome c release in the mitochondria only from the HCC hepatocytes group. Furthermore, SOR and EA applied alone or in combination increased the caspase-3 activity and decreased the hepatocyte viability only on the HCC group. Conclusions: We showed for the first time that EA and SOR are effective on the HCC rat model through mitochondria and hepatocytes targeting.

Tumor suppressor genes are differentially regulated with dietary folate modulations in a rat model of hepatocellular carcinoma.

The current study evaluated the outcome of dietary folate modulations on the expression of tumor suppressor genes (TSGs) during developmental stages of hepatocellular carcinoma (HCC) in a Wistar rat model. In addition to dietary folate modulations, male rats were administered diethylnitrosamine (DEN) intraperitoneally once a week upto 18weeks to induce HCC. Serum folate levels were found to be decreased and increased in folate deficiency (FD) and folate-oversupplemented (FO) groups respectively when compared to folate normal (FN) rats. Apoptosis was observed in FD in fibrosis and HCC stages. mRNA expression analysis by RT-PCR of TSGs (DPT, p16, RUNX3, RASSF1A and SOCS1) and protein expression by western blot (RASSF1A, RUNX3 and p16) depicted differential expression in FD and FO in various stages of HCC development. Bisulfite sequencing for p16 and RASSF1A promoter was performed. The promoter region of p16 gene was hypermethylated at 7th and that of RASSF1A was hypomethylated at 10th CpG in cirrhotic category in FD rats. Hyper and hypomethylation at 10th and 24th CpG respectively in RASSF1A promoter was observed in HCC category in both FD and FO groups. All TSGs showed differential expression at transcript and protein level. Increased expression of DPT, RASSF1A, SOCS1 and decreased expression of RUNX3 could be playing role in HCC development in FD rats. Reduced expression of RUNX3, RASSF1A and SOCS1 in HCC category was demonstrated in FO rats. Thus, the studied TSGs are differentially expressed with dietary folate modulations during the development of HCC in DEN-treated rat model and the promoter methylation might be a contributing mechanism under these conditions.

Comparison of embolic effect between water‐in‐oil emulsion and microspheres in transarterial embolization for rat hepatocellular carcinoma model

To compare two different embolic materials, water-in-oil (W/O) emulsion followed by gelatin particles and microspheres in transarterial embolization (TAE), using a rat hepatocellular carcinoma model. Twenty rats bearing N1S1 cells were divided into the W/O emulsion group and Microsphere group. Water-in-oil emulsion was created by a glass membrane emulsification device. The tumor vascularity was measured by contrast-enhanced ultrasonography 24h before and 10min and 48h after TAE. Tumor necrosis, hepatic infarction ratio surrounding the tumor, and locations of the embolic materials 48h after TAE were assessed. The changes of serum liver enzymes were also evaluated. Statistical significance was determined by using either the Mann-Whitney U-test or Fisher's exact test. The tumor vascularity 48h after TAE was significantly higher in the Microsphere group (20.1 vs. 3.76%, P = 0.016). The overflow of Lipiodol into the portal veins surrounding the tumor was seen, whereas microspheres were seen only in the artery. The percentage of necrotic area and complete response ratio in the W/O emulsion group was significantly higher (99.9 vs. 87.6%, P = 0.029 and 87.5 vs. 28.6%, P = 0.041, respectively). Serum aspartate aminotransferase and serum alanine aminotransferase levels 48h after TAE were significantly higher in the W/O emulsion group (P < 0.01). The embolization using W/O emulsion followed by gelatin particles showed stronger antitumor effects with the occlusion of both the tumor feeding artery and the portal vein compared with microspheres, which occluded only the arteries.

Sufentanil postoperative analgesia reduce the increase of T helper 17 (Th17) cells and FoxP3+ regulatory T (Treg) cells in rat hepatocellular carcinoma surgical model: A randomised animal study

BackgroundSurgery-related pain and opioids might exacerbate immune defenses in immunocompromised cancer patients which might affect postoperativd overall survival. Sufentanil is a good postoperative pain control drug,the present study aimed to figure out whether it effect T cell immunity in rat hepatocellular carcinoma surgical model.MethodsA rat hepatocellular carcinoma (HCC) models was established by N-nitrosodiethylamine. Forty-eight of them were randomly divided into 3 equal groups: surgery without postoperative analgesia (Group C), surgery with morphine postoperative analgesia (Group M), surgery with sufentanil postoperative analgesia (Group S). Each animal underwent a standard left hepatolobectomy, and intraperitoneally implanted with osmotic minipumps filled with sufentanil, morphine or normal saline according to the different group. The food and water consumptions, body weight changes, locomotor activity and mechanical pain threshold (MPT) were observed. The ratio of CD4+/CD8+, proportions of Th1, Th2, Th17 and Treg cells in blood were detected using flow cytometry. The liver function and the rats’ survival situation of each group were observed.ResultsThe food and water consumption, locomotor activity and MPT of group C declined than those of group S and M on d1, d2, d3 (P < 0.05). The CD4+/CD8+ ratio and the proportion of Th1 cells were significantly higher while the proportion of Th2, Th17 and Treg cells were significantly lower in group S and group M compared with group C. The rats of group S have higher CD4+/CD8+ ratio on d3, while lower proportion of Treg cells on d7 compared with group M. The plasma ALT and AST values in group C were significantly higher than that of group S and group M on both d3 and d7. There were not significant differences in mortality rate between 3 groups.ConclusionsSufentanil and morphine postoperative analgesia in HCC rats accepted hepatectomy could relieve postoperative pain, promote the recovery of liver function after surgery, alleviate the immunosuppressive effect of pain. Furthermore, Compared to morphine, sufentanil might have a slighter effect on CD4+/CD8+ ratio and Treg frequencies. Therefore, sufentanil postoperative analgesia is better than morphine in HCC hepatectomy rats.

Water-Soluble Pristine C60 Fullerene Inhibits Liver Alterations Associated with Hepatocellular Carcinoma in Rat

Excessive production of reactive oxygen species is the main cause of hepatocellular carcinoma (HCC) initiation and progression. Water-soluble pristine C60 fullerene is a powerful and non-toxic antioxidant, therefore, its effect under rat HCC model and its possible mechanisms were aimed to be discovered. Studies on HepG2 cells (human HCC) demonstrated C60 fullerene ability to inhibit cell growth (IC50 = 108.2 μmol), to induce apoptosis, to downregulate glucose-6-phosphate dehydrogenase, to upregulate vimentin and p53 expression and to alter HepG2 redox state. If applied to animals experienced HCC in dose of 0.25 mg/kg per day starting at liver cirrhosis stage, C60 fullerene improved post-treatment survival similar to reference 5-fluorouracil (31 and 30 compared to 17 weeks) and inhibited metastasis unlike the latter. Furthermore, C60 fullerene substantially attenuated liver injury and fibrosis, decreased liver enzymes, and normalized bilirubin and redox markers (elevated by 1.7–7.7 times under HCC). Thus, C60 fullerene ability to inhibit HepG2 cell growth and HCC development and metastasis and to improve animal survival was concluded. C60 fullerene cytostatic action might be realized through apoptosis induction and glucose-6-phosphate dehydrogenase downregulation in addition to its antioxidant activity.

Hepatic Artery Embolization Enhances Expression of Programmed Cell Death 1 Ligand 1 in an Orthotopic Rat Hepatocellular Carcinoma Model: In Vivo and in Vitro Experimentation

PurposeTo evaluate the effects of hepatic artery embolization (HAE) on the expression of programmed cell death 1 ligand 1 (PD-L1) in an orthotopic rat hepatocellular carcinoma (HCC) model. Materials and MethodsA rat HCC model was established in Sprague–Dawley rats with the RH7777 cell line. Six animals each were assigned to receive HAE or sham treatment. Liver tissues were harvested 24 h after the procedure. Immunohistochemistry (IHC) was used to compare expression of PD-L1 and hypoxia-inducible factor (HIF)–1α in the intratumoral and peritumoral regions and normal liver tissue. In vitro cell culture study was performed for 24 h under normoxic and hypoxic conditions, and protein expression of PD-L1 and HIF-1α and the effects of HIF-1α inhibitors were assessed. ResultsIHC showed that PD-L1– and HIF-1α–positive areas were significantly larger in the HAE group vs the sham group in intratumoral (P = .006 and P < .001, respectively) and peritumoral regions (both P < .001). The expression of PD-L1 positively correlated with HIF-1α expression in the intratumoral region (r2 = 0.551; P < .001). In vitro cell culture study revealed that protein expression of PD-L1 and HIF-1α were significantly higher when cells were incubated under hypoxic vs normoxic conditions (P = .028 and P = .010, respectively). PD-L1 expression was suppressed significantly when the HIF-1α inhibitor rapamycin was added to the culture medium (P = .024). ConclusionsHAE enhances intratumoral and peritumoral PD-L1 expression in a rat HCC model. The HIF-1α pathway is a possible mechanism underlying increased intratumoral PD-L1 expression after HAE.

Sodium Cholate Bile Acid-Stabilized Ferumoxytol-Doxorubicin-Lipiodol Emulsion for Transcatheter Arterial Chemoembolization of Hepatocellular Carcinoma

PurposeTo develop bile acid-stabilized multimodal magnetic resonance (MR) imaging and computed tomography (CT)-visible doxorubicin eluting lipiodol emulsion for transarterial chemoembolization of hepatocellular carcinoma (HCC). Materials and MethodsFerumoxytol, a US Food and Drug Administration-approved iron oxide nanoparticle visible under MR imaging was electrostatically complexed with doxorubicin (DOX). An amphiphilic bile acid, sodium cholate (SC), was used to form a stable dispersion of ferumoxytol-DOX complex in lipiodol emulsion. Properties of the fabricated emulsion were characterized in various component ratios. Release kinetics of DOX were evaluated for the chemoembolization applications. Finally, in vivo multimodal MR imaging/CT imaging properties and potential therapeutic effects upon intra-arterial (IA) infusion bile acid-stabilized ferumoxytol-DOX-lipiodol emulsion were evaluated in orthotopic McA-Rh7777 HCC rat models. ResultsDOX complexed with ferumoxytol through electrostatic interaction. Amphiphilic SC bile acid at the interface between the aqueous ferumoxytol-DOX complexes and lipiodol enabled a sustained DOX release (17.2 ± 1.6% at 24 hours) at an optimized component ratio. In McA Rh7777 rat HCC model, IA-infused emulsion showed a significant contrast around tumor in both T2-weighted MR imaging and CT images (P = .044). Hematoxylin and eosin and Prussian blue staining confirmed the local deposition of IA-infused SC bile acid-stabilized emulsion in the tumor. The deposited emulsion induced significant increases in TUNEL (terminal deoxynucleotidyl transferase dUTP nick end labeling) stain-positive cancer cell apoptosis compared to those in a group treated with the nonstabilized emulsion. ConclusionsSC bile acid-stabilized ferumoxytol-DOX-lipiodol emulsion demonstrated sustained drug release and multimodal MR imaging/CT imaging capabilities. The new lipiodol-based formulation may enhance the therapeutic efficacy of chemoembolization in HCC.

Near-Infrared Polymer Dots in the Portal-Hepatic Circulation Achieve Localization of Hepatic Carcinoma In Vivo.

The present study aims to use polymer dots to explore whether they can visualize tumor lesions in a diethylnitrosamine (DENA)-induced hepatocellular carcinoma (HCC) model. The HCC rat model was set up, and serum liver function indexes and AFP were tested on days 0, 30, 60, and 90 of the modeling process. After characterization of the polymer dots, they were injected into the rats and mice. The liver, spleen, and kidney of rats and the gallbladder of mice were extracted to verify the metabolic pathways of the polymer dots and their capability of fluorescent localization of HCC and gallbladder by fluorescence imaging. Strong fluorescent emission from the liver appeared immediately and 15 min after the polymer dots were injected through the main portal veins and tail veins of the model rats, respectively. A satisfactory fluorescent imaging effect lasted up to 45 min. Polymer dots circulate through the bloodstream within intrahepatic vessels rather than intracellular areas and can be clearly visualized by using both the pCLE and IVIS spectrum imaging systems. Contrast imaging of HCC lesions without fluorescent emissions was due to the lack of normal portal-hepatic veins within the tumor areas. Fluorescent imaging of the gallbladder could also be detected at 15 min after the polymer dots were injected through the tail veins of mice. The polymer dots had satisfactory fluorescent localization capability for targeted intrahepatic vessels and HCC lesions in vivo and showed potential practical value in hepato-biliary surgery.

P-204 C60 fullerene inhibits hepatocellular carcinoma development and metastasis: In vitro and in vivo studies

Hepatocellular carcinoma (HCC) has an extremely unfavorable prognosis and lack of effective medication therapy. The excessive production of reactive oxygen species is the main cause of its initiation and progression, therefore the use of antioxidants could be a promising treatment. Biocompatible pristine C 60 fullerenes are powerful antioxidants, non-toxic and able to be accumulated in the liver. Therefore, their effects on HepG2 cells and liver state on rat HCC models were aimed to be discovered.

Reduction of FoxP3+ Tregs by an immunosuppressive protocol of rapamycin plus Thymalfasin and Huaier extract predicts positive survival benefits in a rat model of hepatocellular carcinoma.

BackgroundInvestigate immunoregulation and anti-tumor immunity of FoxP3+Tregs after treatment with rapamycin (RAPA/SRL) plus thymalfasin (Zadaxin) and Huaier extract (PS-T) in a hepatocellular carcinoma (HCC) rat model simulating HCC relapse after liver transplant (LT).MethodsWe successfully established a rat model simulating HCC relapse after LT using an optimized chemical induction method with TACROLIMUS, methylprednisolone, and diethylnitrosamine as identified by visible liver nodules and hematoxylin-eosin staining. The model rats were then treated with RAPA, Zadaxin, and PS-T. Immune status changes were analyzed by flow cytometry, and protein expression of Akt and mTOR was determined by western blotting. Cytokines were measured by ELISAs.ResultsCombined therapy by RAPA plus Zadaxin and PS-T obviously alleviated hepatic pathological changes and significantly decreased the levels of FoxP3+Tregs in peripheral blood, the spleen, and the liver (P<0.05) and expression of mTOR protein (P<0.01) in the liver, obviously improved survival time (P=0.02). Moreover, the levels of CD8+T cells were increased significantly to almost normal levels (P<0.05) in comparison with no SRL monotherapy protocols. Inhibitory cytokines were also decreased in accordance with FoxP3+Tregs. Significant decreases of IL-10 and TGF-β were observed after SRL-based therapy (P<0.01) in comparison with the other groups. Serum alpha fetoprotein (AFP) and vascular endothelial growth factor (VEGF) levels were also decreased significantly (P<0.05). FoxP3+Tregs showed a negative correlation with CD8+ and CD4+/CD8+T cells and a positive correlation with AFP, and VEGF (P<0.05).ConclusionsSRL-based therapy reduces FoxP3+Tregs to decrease secreted inhibitory cytokines which may enhancement the viability and number of CD8+T cells to exert anti-tumor effects that are mainly mediated through the AKT-mTOR signaling pathway.

Mechanistic exploration of the activities of poly(lactic-co-glycolic acid)-loaded nanoparticles of betulinic acid against hepatocellular carcinoma at cellular and molecular levels

The effectiveness of betulinic acid (B) and PLGA loaded nanoparticles of B (Bnp) against hepatocellular carcinoma (HCC) was established and reported earlier. In continuation of our previous report, the present study described the molecular mechanisms of their antineoplastic responses. In this context, the antineoplastic properties of both B and Bnp were evaluated on DEN-induced HCC rat model. The quantitative real-time polymerase chain reaction and western blot analyses revealed that HCC was developed through lower expressions of e-NOS, BAX, BAD, Cyt C and higher expressions of i-NOS, Bcl-xl, Bcl-2. B and Bnp normalised the expressions of these apoptogenic markers. Particularly, both activated i-NOS and e-NOS mediated Bcl-2 family proteins→CytC→Caspase 3 and 9 signalling cascades. The 1H-NMR-based metabolomics study also demonstrated that the perturbed metabolites in DEN-induced rat serum restored to the normal level following both treatments. Moreover, the antineoplastic potential of Bnp was found to be comparable with the marketed product, 5-flurouracil.

3:18 PM Abstract No. 192 Histologic assessment of tumor infiltrating lymphocytes following transarterial embolization in a translational rat model of hepatocellular carcinoma

3:18 PM Abstract No. 192 Histologic assessment of tumor infiltrating lymphocytes following transarterial embolization in a translational rat model of hepatocellular carcinoma

Abstract No. 426 Hepatic artery embolization enhance the expression of programmed cell death 1 ligand 1: an in vivo experimental study with an orthotopic rat hepatoma model

Abstract No. 426 Hepatic artery embolization enhance the expression of programmed cell death 1 ligand 1: an in vivo experimental study with an orthotopic rat hepatoma model

A Discovery of Clinically Approved Formula FBRP for Repositioning to Treat HCC by Inhibiting PI3K/AKT/NF-κB Activation

Drug repositioning offers new clinical applications for existing drugs with shorter approval processes and lower costs and risks than de novo experimental drug development. The Fufang-Biejia-Ruangan pill (FBRP) is the first clinically approved anti-fibrosis herbal formula in China. Whether FBRP could be used to treat hepatocellular carcinoma (HCC) remains unclear. Herein, a total of 161 FBRP candidate targets against HCC were identified according to the topological importance in the “hepatic fibrosis-cirrhosis-cancer axis-related gene-FBRP putative target” network, and mostly enriched in phosphatidylinositol 3-kinase (PI3K)/AKT/nuclear factor κB (NF-κB) signaling. Experimentally, FBRP inhibited liver fibrosis and prevented the development of neoplastic lesions at the early stages of hepatocarcinogenesis in a diethylnitrosamine-induced rat HCC model. FBRP inhibited tumor cell proliferation, induced tumor-specific cell death, and suppressed tumor progression in HCC rats while preventing the activation of PI3K, AKT and IKΚB proteins, reducing the nuclear accumulation of NFΚB1 protein, and decreasing the downstream expression of proteins. Consistently, FBRP suppressed HCC cell proliferation and induced cell cycle arrest in vitro. Co-treatment of FBRP with PI3K inhibitor exhibited an additive inhibitory effect on PI3K/AKT/NF-κB activation. Collectively, our data showed the potentials of FBRP in hepatic fibrosis microenvironment regulation and tumor prevention, suggesting that FBRP may be a promising candidate drug for reduction of fibrogenesis and prevention of HCC.

Establishment of an orthotopic syngeneic rat model of hepatocellular carcinoma and its validation with microPET-CT imaging

Establishment of an orthotopic syngeneic rat model of hepatocellular carcinoma and its validation with microPET-CT imaging

Hesperetin upregulates Fas/FasL expression and potentiates the antitumor effect of 5-fluorouracil in rat model of hepatocellular carcinoma

ABSTRACT This study aimed to investigate the antitumor efficacy of hesperetin (HST) either alone or combined with 5-fluorouracil (5-FU) in thioacetamide (TAA)-induced hepatocellular carcinoma (HCC) in rats. Moreover, possible HST molecular mechanism(s) of action were investigated. Sixty male Sprague-Dawley rats were randomized into six groups (n = 10/group); normal control (no treatment), HCC (TAA), HCC/carboxymethyl cellulose (CMC) (TAA+CMC), HST (TAA+HST in CMC), 5-FU (TAA+5-FU), HST/5-FU (TAA+HST+5-FU). Serum levels of liver enzymes (ALT and AST), bilirubin, albumin, total protein and alpha-Fetoprotein (AFP) along with hepatic contents of hepatic glutathione and mal0ndialdhyde were measured. Gene expression of Fas, FasL, caspase-8, caspase-3 and Bcl-2 were measured using real-time polymerase chain reaction. Histopathological examination was used to assess nodule size, fibrosis ratio and necroinflammatory score. HST showed improvements in hepatic functions, decreased levels of AFP and oxidative stress and restricted HCC progression. HST activated apoptosis through inducing Fas and FasL and inhibiting Bcl-2 gene expressions. Furthermore, HST/5-FU combination surpassed the results obtained from either HST or 5-FU groups. In conclusion, HST exerted its antitumor effect through induction of Fas/FasL apoptotic pathway and reduction of oxidative stress. HST and 5-FU combination provided prominent synergistic effects, thus it can be regarded as promising combination therapy for HCC.

Novel combination of celecoxib and metformin improves the antitumor effect by inhibiting the growth of Hepatocellular Carcinoma.

Objective: To explore the effect of COX-2 inhibitor celecoxib in combination with metformin on the prevention of Hepatocellular carcinoma (HCC) and the mechanisms involved.Methods: HCC cell lines and an HCC rat model were treated with celecoxib, metformin or a combination of both. Cell viability and tumor formation were measured.Results: In vitro and in vivo studies showed that treatment with a combination of celecoxib and metformin inhibited proliferation of HCC to a greater extent than either treatment alone, by reducing the phosphorylation of MTOR.Conclusion: The study suggested that celecoxib combined with metformin would be more effective for the preventing occurrence of HCC than either treatment alone and this combination of therapy is worthy of further study.